Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q3 FY26 Earnings Presentation
28 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, Feb 12, 2026
Slide 1: Exchange filing cover letter
12th February 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Investor Present
Slide 2: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q3 & 9M FY26
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q3 & 9M FY26
Slide 3: Q3 & 9M FY26 Performance
Q3 & 9M FY26 Performance
Slide 4: Q3 & 9M FY26 Standalone Performance Highlights
Q3 & 9M FY26 Standalone Performance Highlights Q3 FY26 ₹ 580.4 Cr ₹ 38.8 Cr ₹ 62.6 Cr Revenue from Operations PBT* EBITDA 10.9% YoY 22.8% YoY 39.3% YoY EBITDA Margin 10.7% PBT Margin 6.6% 9M FY26 ₹ 1,699.6 Cr ₹ 196.1 Cr ₹ 124.8 Cr Revenue from Operations EBITDA PBT* 9.6% YoY 24.8% YoY 34.2% YoY EBIT
Slide 5: Q3 & 9M FY26 Standalone Performance Highlights
Q3 & 9M FY26 Standalone Performance Highlights Pharmaceuticals Chemicals (Net of intersegment) Geographical Break-up (In ₹ Cr) (In ₹ Cr) 356.1 231.2 24% 1021.7 661.4 677.9 222.7 224.3 336.4 890.1 300.6 76% 85.4 110.0 26.1 35.5 34.5 8.9 17.4 4.7 5.1 6.5 9M FY25 9M FY26 Q3 FY25 Q2 FY26 Q3 FY26 9M FY25
Slide 6: Standalone Profit & Loss Statement – Q3 & 9M FY26
Standalone Profit & Loss Statement – Q3 & 9M FY26 Particulars (in INR Cr.) Q3 FY26 Q3 FY25 Y-o-Y Q2 FY26 Q-o-Q 9M FY26 9M FY5 Y-o-Y Revenue from Operations 580.4 523.3 10.9% 567.5 2.3% 1699.6 1551.4 9.6% Other Income 5.3 4.1 6.9 19.5 17.9 Total Revenue 585.7 527.4 11.1% 574.4 2.0% 1719.2 1569.3 9.5%
Slide 7: At a Glance
At a Glance
Slide 8: Journey So Far
Journey So Far 1986-91 1996-99 2000-07 2009-13 2015-16 2017-18 2019 - 20 2021-22 2023 2024 2025 • 1986: • 2000 - Commencement of • 2015 - USFDA, EIR for • 2019 - Unit-06 for • Paracetamol capacity has • Commencement Incorporation of Ibuprofen Unit-1 Ibuprofen Pantoprazole (Dedicated) been increased
Slide 9: Business Overview
Business Overview Team size of 3000+ Among the top global Existing Facility: Zero Discharge Largest producer of employees producers of Iso Butyl Spanning 180+ acres Effluent Treatment Ibuprofen and the only Benzene (IBB) Plant company worldwide being Expansion: Acquired 101 fully backward integrated
Slide 10: Segment Overview- Pharmaceuticals
Segment Overview- Pharmaceuticals Largest global producer of Ibuprofen with complete Expanding non-Ibuprofen API segment with a A fully backward-integrated and automated facility backward integration, having an annual capacity of diversified portfolio across multiple therapeutic areas, for manufactu
Slide 11: Segment Overview- Specialty Chemicals
Segment Overview- Specialty Chemicals Producing Acetic Anhydride Asia’s first continuous dual REACH-certified for Ethyl Among the largest global Ethyl Acetate with capacity of 25,000 technology plant for MCA Acetate & Acetic Anhydride, manufacturers of Iso Butyl manufacturing capacity of MTPA - for
Slide 12: Pharmaceuticals- A Key Focus
Pharmaceuticals- A Key Focus Expanding the non-Ibuprofen Business Installed Capacity Regulatory Filings* Therapeutic Area USDMF, CEP & ANVISA GMP Metformin Hydrochloride 7200 MTPA Anti-Diabetic Approved, China DMF Active 59% 58% USDMF, CEP & ANVISA GMP 57% Fenofibrate Multiproduct Plant Anti-Cholest
Slide 13: Manufacturing Facilities
Manufacturing Facilities API manufactured in batch manner and intermediates Facility is coupled with ISO class-8 HVAC system, PSA Dedicated and multiproduct blocks involved in & Specialty chemicals in continuous product delivery Nitrogen & Purified water along with 185 MTPH steam manufacturing of AP
Slide 14: Research & Development
Research & Development From Lab to Launch: 20 Products Commercialized, 9 More in Pipeline — R&D at the Heart of Our Growth Story 3 15 21 Patents DMFs with USFDA CEPs with EDQM (19 Approved, 2 Under Review) A 120-member highly Working on generic skilled team, including 50+ molecules with latest DSIR
Slide 15: Certifications & Accreditations
Certifications & Accreditations DMF Registration From ISO 9001:2015, 14001:2015 & USFDA Approved Facility EUGMP Certification EDQM Certificate of Suitability Halal Certified MFDS Korea 45001:2018 GMP certificate by Ministry of Industry and Trade of the Russian Federation GMP Certificate by Russian K
Slide 16: Core Management Team
Core Management Team Varinder Gupta | (Managing Director) Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence. Vikas Gupta | (Joint Managing
Slide 17: Board of Directors
Board of Directors Rajender Mohan Malla Sharad Tyagi Harpal Singh Ms Rajni Jha (Chairman and Independent (Independent Director) (Independent Director) (Independent Director) Director) o With four decades of experience held o Over 38 years of intrapreneurship in o Over 37 year's experience of banking
Slide 18: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Awarded EcoVadis Silver Medal recognizing strong ESG Performance & Global Sustainability Leadership; Ranks Among the Top 15% companies globally o Committed to becoming carbon neutral by 2050 o 100 % State of the art Zero liquid Discharge (ZLD)
Slide 19: Industry Overview
Industry Overview
Slide 20: API Industry- Overview
API Industry- Overview Global API Market Size (In USD Bn) Indian API Market Size (In USD Bn) 4.40% 368.98 38.60 8.10% North America holds over 38% of India is the 3rd largest API the API market in 2024. 245.59 producer globally, contributing 8% Asia-Pacific—led by India and to the market, with over
Slide 21: Specialty Chemicals Industry- Overview
Specialty Chemicals Industry- Overview Global Spec. Chem Market Size Indian Spec. Chem Market Size Region wise Spec. Chem Market Size Growth (FY25-30) (In USD Bn) (In USD Bn) 3.23% 11% 3.80% 1054.70 92.60 7% 780.30 64.50 4% 3 3% 3% 2% 2024 2033 2024 2034 North Latin Europe Middle Japan China India A
Slide 22: Historical Performance
Historical Performance
Slide 23: Historical Standalone Performance
Historical Standalone Performance Revenues EBITDA & EBITDA % Cash Profit After Tax 13.0% 11.2% 12.1% 10.7% 2216 2243 2163 2102 288 209 208 252 262 189 185 225 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Segmental Revenue Cash Flow from Operations Capex Spent 1175 1259 1263 1212 290 2
Slide 24: Summary Statement of Standalone Profit and Loss
Summary Statement of Standalone Profit and Loss Particulars (in INR Cr.) FY25 FY24 FY23 FY22 Revenue from Operations 2079.2 2,132.8 2,217.1 2,184.0 Other Income 22.4 30.1 25.6 32.0 Total Revenue 2101.6 2,162.9 2,242.7 2,216.1 Cost of Materials Consumed 1358.3 1,435.1 1,536.1 1,578.9 Purchase of Trad
Slide 25: Summary Statement of Standalone Balance Sheet
Summary Statement of Standalone Balance Sheet Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1,158.0 921.1 750.5 559.5 58.7 58.7 58.7 58.7 (i) Equity s
Slide 26: Summary Statement of Standalone Cashflow
Summary Statement of Standalone Cashflow Particulars (in INR Cr.) Mar 25 Mar 24 Mar 23 Mar 22 Cash Flow from Operating Activities Profit before Tax 137.9 182.6 189.5 222.8 Adjustment for Non-Operating Items 79.8 59.8 44.4 33.1 Operating Profit before Working Capital Changes 217.7 242.4 233.9 256.0 C
Slide 27: Way Forward
Way Forward Backward Integration for Margin Product Diversification Beyond Export Contribution to Rise Scaling Through Land Acquisition and Supply Chain Resilience Ibuprofen The non-Ibuprofen share in the pharmaceuticals segment has The company adopts a strategic The company has acquired 101 acres i
Slide 28: Thank You
COMPANY : IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Mr. Abhay Raj Singh - Sr. VP & Company Secretary investor@iolcp.com E-mail: investor@iolcp.com www.iolcp.com www.iolcp.com INVESTOR RELATIONS ADVISORS : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a
IOL Chemicals and Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix